Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

RemeGen Co., Ltd.

REGMFPNK
Healthcare
Biotechnology
$10.45
$0.00(0.00%)
U.S. Market opens in 9h 38m

RemeGen Co., Ltd. Fundamental Analysis

RemeGen Co., Ltd. (REGMF) shows moderate financial fundamentals with a PE ratio of -42.56, profit margin of -42.62%, and ROE of -44.94%. The company generates $2.2B in annual revenue with strong year-over-year growth of 58.54%.

Key Strengths

Cash Position20.09%
PEG Ratio-0.36

Areas of Concern

ROE-44.94%
Operating Margin-42.01%
Current Ratio0.96
We analyze REGMF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -42.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-42.4/100

We analyze REGMF's fundamental strength across five key dimensions:

Efficiency Score

Weak

REGMF struggles to generate sufficient returns from assets.

ROA > 10%
-15.86%

Valuation Score

Excellent

REGMF trades at attractive valuation levels.

PE < 25
-42.56
PEG Ratio < 2
-0.36

Growth Score

Moderate

REGMF shows steady but slowing expansion.

Revenue Growth > 5%
58.54%
EPS Growth > 10%
2.50%

Financial Health Score

Moderate

REGMF shows balanced financial health with some risks.

Debt/Equity < 1
0.94
Current Ratio > 1
0.96

Profitability Score

Weak

REGMF struggles to sustain strong margins.

ROE > 15%
-4493.67%
Net Margin ≥ 15%
-42.62%
Positive Free Cash Flow
No

Key Financial Metrics

Is REGMF Expensive or Cheap?

P/E Ratio

REGMF trades at -42.56 times earnings. This suggests potential undervaluation.

-42.56

PEG Ratio

When adjusting for growth, REGMF's PEG of -0.36 indicates potential undervaluation.

-0.36

Price to Book

The market values RemeGen Co., Ltd. at 17.39 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

17.39

EV/EBITDA

Enterprise value stands at -57.09 times EBITDA. This is generally considered low.

-57.09

How Well Does REGMF Make Money?

Net Profit Margin

For every $100 in sales, RemeGen Co., Ltd. keeps $-42.62 as profit after all expenses.

-42.62%

Operating Margin

Core operations generate -42.01 in profit for every $100 in revenue, before interest and taxes.

-42.01%

ROE

Management delivers $-44.94 in profit for every $100 of shareholder equity.

-44.94%

ROA

RemeGen Co., Ltd. generates $-15.86 in profit for every $100 in assets, demonstrating efficient asset deployment.

-15.86%

Following the Money - Real Cash Generation

Operating Cash Flow

RemeGen Co., Ltd. generates limited operating cash flow of $-64.76M, signaling weaker underlying cash strength.

$-64.76M

Free Cash Flow

RemeGen Co., Ltd. generates weak or negative free cash flow of $-327.59M, restricting financial flexibility.

$-327.59M

FCF Per Share

Each share generates $-0.58 in free cash annually.

$-0.58

FCF Yield

REGMF converts -0.81% of its market value into free cash.

-0.81%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-42.56

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.36

vs 25 benchmark

P/B Ratio

Price to book value ratio

17.39

vs 25 benchmark

P/S Ratio

Price to sales ratio

18.20

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.94

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.96

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.45

vs 25 benchmark

ROA

Return on assets percentage

-0.16

vs 25 benchmark

ROCE

Return on capital employed

-0.30

vs 25 benchmark

How REGMF Stacks Against Its Sector Peers

MetricREGMF ValueSector AveragePerformance
P/E Ratio-42.5629.45 Better (Cheaper)
ROE-44.94%779.00% Weak
Net Margin-42.62%-24936.00% (disorted) Weak
Debt/Equity0.940.26 Weak (High Leverage)
Current Ratio0.964.65 Weak Liquidity
ROA-15.86%-19344.00% (disorted) Weak

REGMF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews RemeGen Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-203.77%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-270.42%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ